Collegium Pharmaceutical (NASDAQ:COLL) vs. InMed Pharmaceuticals (NASDAQ:INM) Head-To-Head Contrast

Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) and InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.9% of Collegium Pharmaceutical shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Collegium Pharmaceutical and InMed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Collegium Pharmaceutical 4.68% 85.14% 13.80%
InMed Pharmaceuticals N/A -282.17% -187.15%

Earnings and Valuation

This table compares Collegium Pharmaceutical and InMed Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Collegium Pharmaceutical $780.57 million 1.01 $62.87 million $1.00 25.43
InMed Pharmaceuticals $4.94 million 9.72 -$12.56 million ($1.64) -8.84

Collegium Pharmaceutical has higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Collegium Pharmaceutical and InMed Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Collegium Pharmaceutical 0 2 7 1 2.90
InMed Pharmaceuticals 1 0 1 0 2.00

Collegium Pharmaceutical currently has a consensus price target of $44.00, suggesting a potential upside of 73.02%. InMed Pharmaceuticals has a consensus price target of $42.00, suggesting a potential upside of 189.66%. Given InMed Pharmaceuticals’ higher possible upside, analysts plainly believe InMed Pharmaceuticals is more favorable than Collegium Pharmaceutical.

Risk & Volatility

Collegium Pharmaceutical has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500.

Summary

Collegium Pharmaceutical beats InMed Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

About Collegium Pharmaceutical

(Get Free Report)

Collegium Pharmaceutical is a U.S.-based specialty pharmaceutical company focused on developing and commercializing medicines for pain management. Its portfolio includes Xtampza ER, an extended-release oxycodone product; Belbuca, a buprenorphine buccal film for chronic pain; and Nucynta, tapentadol tablets available in immediate- and extended-release formulations. The company also markets Symproic, a treatment for opioid-induced constipation. Collegium’s products include extended-release and opioid medicines, and the company emphasizes responsible use and risk-mitigation measures in its commercial activities.

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc. is a biotechnology company focused on rare cannabinoids and their commercial applications. Through its BayMedica business, the company has developed and manufactured cannabinoid ingredients for use in health and wellness, personal care, and pharmaceutical products. BayMedica has used chemical synthesis and other production methods to make rare cannabinoids, including compounds that occur naturally in cannabis in small quantities. InMed has served business customers seeking cannabinoid ingredients for product development and manufacturing.

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.